Company: NCEL
Filing Date: 2025-04-04
Form Type: 6-K/A
Source: 0001213900-25-028988
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-04-04
Form: 6-K/A
Chunk 4
---
 Nos. 333-284696,
333-284811, 333-282788,
333-262489, 333-268690
and 333-269220), filed with the
Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.

<div align='center'>3

EXHIBIT INDEX</div>

| Exhibit No. |     | Document Description                                                                                                                                                                                                 |
| 99.1        |     | Form of Securities Purchase Agreement, dated March 27, 2025, by and between NLS Pharmaceutics and the certain purchasers thereto.  (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed on March 31, 2025). |
| 99.2        |     | Form of Registration Rights Agreement (filed as Exhibit 99.2 to Form 6-K (File No. 001-39957) filed on March 31, 2025).                                                                                              |
| 99.3        |     | Common Shares Purchase Agreement, dated March 30, 2025, between NLS Pharmaceutics and the certain purchaser thereto (filed as Exhibit 99.3 to Form 6-K (File No. 001-39957) filed on March 31, 2025).                |
| 99.4        |     | Form of Pre-Funded Warrant (filed as Exhibit 99.4 to Form 6-K (File No. 001-39957) filed on March 31, 2025).                                                                                                         |
| 99.5        |     | Form of Common Warrant.                                                                                                                                                                                              |

<div align='center'>4

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: April 4, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:--------------------|:-----------------------|:--------------------|:------------------------|
|                     |                        | Name:               | Alexander Zwyer         |
|                     |                        | Title:              | Chief Executive Officer |

<div align='center'>5</div>